Bicycle Therapeutics (BCYC) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Technology platform and differentiation

• Bicycle peptides are 50–100 times smaller than antibodies, enabling deep tissue penetration and short systemic half-life, ideal for targeted delivery of toxins or radioisotopes.

• Molecules are highly selective, binding only to their target protein, and are fully synthetic and easily conjugatable.

• Platform offers improved safety and efficacy profiles compared to antibody-drug conjugates (ADCs), with reduced off-target effects.

Pipeline progress and clinical updates

• Lead molecule zelnecirib (BT8009) targets Nectin-4 and is advancing through registration studies, showing promising data in bladder cancer.

• BT5528 targets ephrin A2, with over 100 patients dosed and no severe toxicology seen, unlike ADCs.

• BT7480, another Nectin-4 agent, demonstrated strong tolerability and immune activation in dose escalation studies.

• All three candidates show differentiated safety, low neuropathy, and promising efficacy, with plans to expand into additional tumor types.

Key clinical data and safety profile

• ESMO presentations highlighted consistent response rates for zelnecirib, with a 50% longer duration of response compared to benchmarks.

• BT5528 showed a 45% response rate and validated biweekly dosing for optimal efficacy and tolerability.

• Across 146 patients, only one reversible Grade 3 neuropathy was observed, with overall lower incidence and severity than ADCs.

• Safety profile is a major differentiator, with reduced skin toxicity, neuropathy, and other adverse events.